Baricitinib helps regrow hair in teens with severe alopecia areata.
July 2025 in “Dermatologic Surgery” PRP may increase hair density but doesn't improve quality of life in breast cancer survivors with hair loss.
January 2018 in “General internal medicine and clinical innovations” Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
2 citations
,
August 2021 in “Photodiagnosis and Photodynamic Therapy” Using 5-aminolevulinic acid photodynamic therapy for hair loss didn't increase hair growth but slightly reduced scalp oiliness, and it was safe with mild side effects.
January 2026 in “JPRAS Open” PDLLA scalp injections improved hair regrowth in most patients with non-scarring alopecia.
September 2023 in “Journal of the American Academy of Dermatology” January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
1 citations
,
October 2006 in “Urology” Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.
December 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
Baricitinib shows promise for treating alopecia areata with mild side effects.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
September 2017 in “Journal of Investigative Dermatology” RCS-01 is safe and may help rejuvenate aging skin.
2 citations
,
January 2022 in “Lasers in Medical Science” Using a carbon dioxide laser and platelet-rich plasma together can effectively restore hair and patients are generally satisfied with the results.
STS01 1% effectively promotes hair regrowth with minimal side effects.
5 citations
,
May 2018 in “Drug Safety” Using electronic health records can help identify drug side effects but has some limitations.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
February 2025 in “Advances in Therapy” The topical finasteride spray was safe and well-tolerated with stable effects.
Compound 6 is a promising candidate for better wound healing.
January 2002 in “Journal of Clinical Dermatology”
10 citations
,
January 2007 in “Journal of cosmetic and laser therapy” The IPL device is safe, effective, and has high patient satisfaction for hair removal.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
June 2017 in “Journal of The American Academy of Dermatology” The new treatment was safe and may effectively treat male pattern hair loss.